New in vivo results support concerns about harmful effects of cortisone drugs in the treatment of breast cancer

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 941-942

  Herr, Ingrid ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Chemotherapy; Dexamethosone; Glucorticoids; Resistance; Steroid hormones

Indexed keywords

CORTISONE; DEXAMETHASONE; GLUCOCORTICOID; PACLITAXEL; PROTEIN BID; TAXANE DERIVATIVE; TENIPOSIDE; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG TUMOR; NONHUMAN; NOTE; OVARY CANCER;

EID: 33751181680     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.3285     Document Type: Note

References (24)

1. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000; 279:307-12.
2. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360:1969-70.
3. Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002; 60:553-61.
4. Bernard-Marty C, Cardoso F, Piccart MJ. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 2003; 39:1978-89.
5. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000; 60:867-72.
6. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptormediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276:16649-54.
7. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64:1757-64.
8. Sahoo S, Brickley DR, Kocherginsky M, Conzen SD. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer 2005; 17:2754-9.
9. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MKP-1 expression inhibits paclitaxel-associated MAP kinase activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280:4117-24.
10. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. Glucocorticoid receptor activation signals through FOXO3a in breast cancer cells. Mol Endocrinol 2006.
11. Sui M, Chen F, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2006; 119:712-7.
12. Zhang C, Kolb A, Buechler P, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer 2006; 6:61.
13. Zhang C, Kolb A, Mattern J, et al. Dexamethasone desensitizes hepatocellular and colorectal tumors toward cytotoxic therapy. Cancer Letters 2005; in press.
14. Zhang C, Marme A, Wenger T, et al. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncology 2006; 2:551-7.
15. Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide- doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol 1994; 17:522-6.
16. Tsuei SE, Moore RG, Ashley JJ, McBride WG. Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 1979; 7:249-64.
17. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 1987; 32:593-6.
18. Iversen HG, Hjort GH. The influence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer. Acta Pathol Microbiol Scand 1958; 44:205-12.
19. Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. JAMA 1962; 181:313-7.
20. Rasmuson T, Ljungberg B, Grankvist K, Jacobsen J, Olsson T. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol 2001; 40:83-7.
21. Postmus PE, Smit EF, Haaxma-Reiche H, et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1995; 13:660-5.
22. Muenstedt K, Borces D, Bohlmann MK, Zygmunt M, von Georgi R. Glucocorticoid administration in antiemetic therapy. Cancer 2004; 101:1696-702.
23. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96:709-11.
24. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumors: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncology 2006; 7:425-30.